YC-6 Neuroprotective Use for Gamma Radiation Brain Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for radiation-induced brain injury, particularly those induced by gamma rays, lack effective large-scale clinical evidence and there is an urgent need for drugs that can prevent or treat this condition, especially for late-delayed radiation-induced brain injuries such as edema and necrosis stages.
Innovation Solution
The use of 5α-androst-3β,5,6β-triol and its derivatives, referred to as YC-6, in the form of pharmaceutically acceptable salts, administered to prevent or treat radiation-induced brain injuries, particularly those induced by gamma rays, through various routes including oral, transdermal, transmucosal, and parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat radiation-induced brain injury, then neurological symptoms may be alleviated, but there is a lack of large-scale clinical evidence and the treatment is mostly based on clinical experience rather than robust trial data
Solution Approach 1:
The patent applies preliminary action by administering the compound before or during radiation therapy to prevent radiation-induced brain injury from developing in the first place, rather than treating symptoms after injury occurs. This preventive approach is supported by animal studies showing reduced brain lesion volume when compound is given prior to radiation exposure.
Solution Approach 2:
The patent replaces the conventional glucocorticoid treatment mechanism with a novel compound that acts through different biological pathways. The compound appears to protect against radiation injury through mechanisms involving reduced inflammatory response and protection of the blood-brain barrier, substituting the traditional steroid-based approach with a new pharmacological agent.
2Reliability
If bevacizumab is used to treat radiation-induced brain injury, then brain injury lesions are reduced and neurological function improves, but the treatment cost increases and long-term use may have side effects
Solution Approach 1:
The patent employs a small molecule compound that can be administered through conventional routes (oral, intravenous, intramuscular, subcutaneous) rather than requiring expensive monoclonal antibody therapies like bevacizumab. The compound demonstrates efficacy in reducing brain lesion volume and improving neurological outcomes at lower cost with a favorable safety profile in preclinical models.
Solution Approach 2:
The patent changes the pharmacological parameters by using a compound with different binding characteristics and mechanism of action compared to bevacizumab. The compound affects multiple pathways including VEGF inhibition, inflammatory cytokine reduction, and blood-brain barrier protection, achieving similar clinical benefits through altered pharmacological parameters.
3Ease of operation
If dehydrating drugs are used for radiation-induced brain injury, then acute space occupying effects are managed, but treatment is limited to short periods of 5-7 days and is not suitable for routine long-term management
Solution Approach 1:
The patent applies preliminary action by establishing protective effects before radiation-induced edema and necrosis fully develop. Animal studies show that compound administration prior to and during radiation therapy prevents the formation of large brain lesions, thereby avoiding the need for subsequent dehydrating drug interventions.
Solution Approach 2:
The patent enables continuous long-term treatment beyond the 5-7 day limitation of dehydrating drugs. The compound maintains protective effects throughout the radiation therapy course and into the recovery period, providing sustained neuroprotection and reducing brain lesion volume over extended periods without the restrictions of conventional short-term therapies.
Data Source
Figure 1~2A
Figure 2B~3A
Figure 3B~4A
AI summary
Disclosed is use of 5α-androst-3β,5,6β-triol and derivatives thereof in the prevention or treatment of radiation-induced brain injury, and a method for preventing or treating radiation-induced brain injury with 5α-androst-3β,5,6β-triol and derivatives thereof.